Cargando…

Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma

Extramedullary multiple myeloma (EMD) is an aggressive disease; malignant plasma cells lose their dependence in the bone marrow microenvironment and migrate into tissues. EMD is a negative prognostic factor of survival. Using flow cytometry and next-generation sequencing, we aimed to identify antige...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vlachová, Monika, Gregorová, Jana, Vychytilová-Faltejsková, Petra, Gabło, Natalia Anna, Radová, Lenka, Pospíšilová, Lenka, Almáši, Martina, Štork, Martin, Knechtová, Zdeňka, Minařík, Jiří, Popková, Tereza, Jelínek, Tomáš, Hájek, Roman, Pour, Luděk, Říhová, Lucie, Ševčíková, Sabina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741227/ https://www.ncbi.nlm.nih.gov/pubmed/36499093 http://dx.doi.org/10.3390/ijms232314765

Ejemplares similares

LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients
por: Bútová, Romana, et al.
Publicado: (2021)

Identification of patients at high risk of secondary extramedullary multiple myeloma development
por: Stork, Martin, et al.
Publicado: (2021)

Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
por: Stork, Martin, et al.
Publicado: (2022)

Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia
por: Bezdekova, Renata, et al.
Publicado: (2021)

Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma
por: Besse, Lenka, et al.
Publicado: (2015)

Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
por: Stork, Martin, et al.
Publicado: (2023)

Epigenetic Regulation of MicroRNA Clusters and Families during Tumor Development
por: Gregorova, Jana, et al.
Publicado: (2021)

Dynamics of tumor‐specific cfDNA in response to therapy in multiple myeloma patients
por: Vrabel, David, et al.
Publicado: (2019)

P967: TUMOR BURDEN AS A CRITICAL PROGNOSTIC FACTOR OF PRIMARY EXTRAMEDULLARY DISEASE
por: Vlachová, M., et al.
Publicado: (2022)

Circulating exosomal long noncoding RNA PRINS—First findings in monoclonal gammopathies
por: Sedlarikova, Lenka, et al.
Publicado: (2018)

More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia–Like Multiple Myeloma
por: Jelinek, Tomas, et al.
Publicado: (2023)

PB1974: MULTIVARIATE SPECTRAL BIOTYPING OF EXTRAMEDULLARY MULTIPLE MYELOMA
por: Vlachová, M., et al.
Publicado: (2022)

Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma
por: Kubiczkova, Lenka, et al.
Publicado: (2014)

Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience
por: Krejci, Marta, et al.
Publicado: (2021)

P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS
por: Popková, Tereza, et al.
Publicado: (2023)

Long Non-Coding RNAs in Multiple Myeloma
por: Butova, Romana, et al.
Publicado: (2019)

Centrosome associated genes pattern for risk sub-stratification in multiple myeloma
por: Kryukov, Fedor, et al.
Publicado: (2016)

Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy
por: Nemecek, Radim, et al.
Publicado: (2016)

P805: EXTRAMEDULLARY MULTIPLE MYELOMA: MOLECULAR PATHOGENESIS AND NOVEL THERAPEUTIC TARGETS
por: Zihala, David, et al.
Publicado: (2023)

MicroRNAs in urine are not biomarkers of multiple myeloma
por: Sedlaříková, Lenka, et al.
Publicado: (2015)

Functionally Suppressive CD8 T Regulatory Cells Are Increased in Patients with Multiple Myeloma: A Cause for Immune Impairment
por: Muthu Raja, Karthick Raja, et al.
Publicado: (2012)

Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine
por: Zátopková, Martina, et al.
Publicado: (2022)

Rapid discrimination of multiple myeloma patients by artificial neural networks coupled with mass spectrometry of peripheral blood plasma
por: Deulofeu, Meritxell, et al.
Publicado: (2019)

Chromothripsis 18 in multiple myeloma patient with rapid extramedullary relapse
por: Smetana, Jan, et al.
Publicado: (2018)

Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy
por: Minarik, Jiri, et al.
Publicado: (2022)

TGF-β – an excellent servant but a bad master
por: Kubiczkova, Lenka, et al.
Publicado: (2012)

MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab
por: Mlcochova, Jitka, et al.
Publicado: (2015)

Plasmacytoid Dendritic Cells in Patients with MGUS and Multiple Myeloma
por: Knight, Andrea, et al.
Publicado: (2021)

Increased T Regulatory Cells Are Associated with Adverse Clinical Features and Predict Progression in Multiple Myeloma
por: Muthu Raja, Karthick Raja, et al.
Publicado: (2012)

Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma
por: Dementyeva, Elena, et al.
Publicado: (2013)

Bioinformatic pipelines for whole transcriptome sequencing data exploitation in leukemia patients with complex structural variants
por: Hynst, Jakub, et al.
Publicado: (2019)

Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies
por: Sandecka, Viera, et al.
Publicado: (2023)

MiR-215-5p is a tumor suppressor in colorectal cancer targeting EGFR ligand epiregulin and its transcriptional inducer HOXB9
por: Vychytilova-Faltejskova, Petra, et al.
Publicado: (2017)

Immunomodulatory Agents for Multiple Myeloma
por: Minařík, Jiří, et al.
Publicado: (2022)

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
por: Minarik, Jiri, et al.
Publicado: (2021)

The Benefit of Telemonitoring in the Prevention of Septic Shock in a Patient with Aggressive Non-Hodgkin’s Lymphoma
por: Dudová, Lucie, et al.
Publicado: (2023)

The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma
por: Vdovin, Alexander, et al.
Publicado: (2022)

The First Extracellular Linker Is Important for Several Aspects of the Gating Mechanism of Human TRPA1 Channel
por: Marsakova, Lenka, et al.
Publicado: (2017)

Controlled Structuring of Hyaluronan Films by Phase Separation and Inversion
por: Smolka, Petr, et al.
Publicado: (2023)

Management of Treatment-Related Infectious Complications in High-Risk Hemato-Oncological Patients via Telemedicine
por: Hradská, Katarína, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lele7tjnu12nv4m2apfbvflrvg